N/A N=720 A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation
Cigarette Smoking
Primary: High Density Lipoprotein C (HDL-C). — 57.1; 58.9; 58.6 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=50 The Adrenal Contribution to Androgen Production in Girls During Puberty
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
N/A N=189 SJM MRI Diagnostic Imaging Registry (IDE)
Cardiac Arrhythmia
Primary: The Proportion of MRI Scans From Pacemakers or CRT-Ps Providing Sufficient Image Quality to Allow for a Diagnostic Interpretation. — 129 MRI Scans
Early Phase 1 N=13 Treatment of HFpEF With Nitrate Supplement
Heart Failure With Normal Ejection Fraction
Primary: Time on Treadmill — 402.8; 181.2 seconds
N/A N=44 The SIM-PLICITY Study: The SIMulation Project - LIstening & Intervention in Pediatric obeSITY
Childhood Obesity
Primary: Simulation Total Role Play Score — 25.73; 23.73; 33.29; 25.89 score on a scale
Phase 3 N=68 Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
Congenital Bleeding Disorder · Haemophilia A
Primary: Haemostatic Effect of Turoctocog Alfa (Treatment of Bleeds): 6 Months — 35; 156; 20; 190 Bleeding episodes
Phase 1 N=40 Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement
Healthy, Young Adults
Primary: Balance Score — 9.9; 11.5; 7.0; 11.3 seconds — p=0.172
Phase 2 N=22 Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men
Aging · Obesity · Insulin Resistance
Primary: Change in Total Mass and Regional Adipose Adiposiy — 0.3; -1.4; -0.9; -0.7 kilograms — p=0.77
Phase 3 N=262 Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50% — 20.0; 14.0 Months
N/A N=2,204 Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial
Atrial Fibrillation · Arrhythmia
Primary: Number of Participants With Composite of Total Mortality, Disabling Stroke, Serious Bleeding, or Cardiac Arrest in Patients Warranting Therapy for AF. — 89; 101…
Phase 3 N=600 Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)
Varicella
Primary: Percentage of Participants With Varicella Zoster Virus Antibody Levels ≥5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL — 98.4; 98.3 Percentage of…
N/A N=60 The Viability of Short Stems in Total Hip Arthroplasty
Osteoarthritis of Hip
Primary: Mean VR-12 Mental Composite Score Through 2 Years Post Operative — 47.3; 50.6; 54.9; 53.8 T-Score
N/A N=523 Risk Stratification in Patients With Preserved Ejection Fraction
Myocardial Infarction
Primary: Number of Participants With Major Arrhythmic Events (MAEs) - Present When One of the Following Occurred: Sudden Cardiac Death, Sustained Ventricular Tachycardia, or…
Phase 3 N=121 BAX 855 PK-guided Dosing
Hemophilia A
Primary: Percentage of Participants With a Total Annualized Bleeding Rate (ABR) of Zero for Second Six Months — 42.1; 62.1 Percentage of participants — p=0.0545
Phase 1 N=24 Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT
Allogeneic Hematopoietic Stem Cell Transplantation
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 0 Participants